GlaxoSmithKline is banking that it can come back from behind in the race for a Covid-19 vaccine and play an important role preparing for new pandemics after releasing positive trial data. He said the vaccine with Sanofi looks particularly promising as a booster, and CureVac’s mRNA vaccine could target several variants at once. The study results are also a boost to Sanofi, which was the second-largest vaccine maker by sales before the pandemic after GSK, but fell behind last year in the race to develop Covid-19 vaccines. Sanofi’s failure to bring a Covid-19 vaccine to market has been the subject of much debate in France because critics see it is a symbol of the country’s scientific decline. Connor said GSK’s vaccine business is a “crown jewel” that has been under-appreciated, increasing revenue by 50 per cent and doubling profit in the past four years.

Source: The Irish Times May 17, 2021 07:07 UTC